Amneal Pharmaceuticals, Inc. (AMRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 300M 600M 900M Q3 '21: 528.6M Q4 '21: 536.9M Q1 '22: 497.6M Q2 '22: 559.4M Q3 '22: 545.6M Q4 '22: 609.8M Q1 '23: 557.5M Q2 '23: 599M Q3 '23: 620M Q4 '23: 617M Q1 '24: 659.2M Q2 '24: 701.8M Q3 '24: 702.5M Q4 '24: 730.5M Q1 '25: 695.4M Q2 '25: 724.5M Q3 '25: 784.5M Q4 '25: 814.3M Q1 '26: 722.5M Q2 '26: 796.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 150M 300M 450M Q3 '21: 198.5M Q4 '21: 166.4M Q1 '22: 174.6M Q2 '22: 200.5M Q3 '22: 194.2M Q4 '22: 215.4M Q1 '23: 178.2M Q2 '23: 220M Q3 '23: 232.5M Q4 '23: 189.8M Q1 '24: 238.1M Q2 '24: 249.9M Q3 '24: 269.6M Q4 '24: 262.9M Q1 '25: 255.9M Q2 '25: 286.3M Q3 '25: 274M Q4 '25: 297.2M Q1 '26: 320.1M Q2 '26: 334.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-210M -140M -70M 0 70M 140M 210M Q3 '21: 28.5M Q4 '21: 11.2M Q1 '22: 23.3M Q2 '22: -198.6M Q3 '22: 44.4M Q4 '22: 36M Q1 '23: 34.4M Q2 '23: 80.1M Q3 '23: 75.6M Q4 '23: 14.2M Q1 '24: -10.7M Q2 '24: 95.5M Q3 '24: 88.8M Q4 '24: 75.8M Q1 '25: 100.3M Q2 '25: 111.4M Q3 '25: 70.3M Q4 '25: 112M Q1 '26: 141.8M Q2 '26: 129.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-270M -180M -90M 0 90M 180M 270M Q3 '21: -7.8M Q4 '21: -21.8M Q1 '22: -8.8M Q2 '22: -242.1M Q3 '22: -7.6M Q4 '22: -12M Q1 '23: -6.9M Q2 '23: 11.9M Q3 '23: 9.7M Q4 '23: -98.6M Q1 '24: -91.6M Q2 '24: 6M Q3 '24: -156K Q4 '24: -31.1M Q1 '25: 12.2M Q2 '25: 22.4M Q3 '25: 2.4M Q4 '25: 35.1M Q1 '26: 62.3M Q2 '26: 57.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 200M 400M 600M Q3 '21: 329.4M Q4 '21: 371.2M Q1 '22: 323.1M Q2 '22: 358.8M Q3 '22: 351.3M Q4 '22: 394.4M Q1 '23: 379.4M Q2 '23: 379M Q3 '23: 387.5M Q4 '23: 427.2M Q1 '24: 421.1M Q2 '24: 451.8M Q3 '24: 432.9M Q4 '24: 467.6M Q1 '25: 439.5M Q2 '25: 438.3M Q3 '25: 510.5M Q4 '25: 517.1M Q1 '26: 402.4M Q2 '26: 461.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '21: 82.4M Q4 '21: 63.3M Q1 '22: 120.3M Q2 '22: -125.5M Q3 '22: 93.6M Q4 '22: -23.3M Q1 '23: 139.7M Q2 '23: -11.3M Q3 '23: 81.4M Q4 '23: 135.8M Q1 '24: -4.4M Q2 '24: 39.7M Q3 '24: 141.8M Q4 '24: 118.1M Q1 '25: 7.4M Q2 '25: 83.8M Q3 '25: 118.5M Q4 '25: 130.3M Q1 '26: -26.7M Q2 '26: -21.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '21: 71.7M Q4 '21: 45.8M Q1 '22: 109.5M Q2 '22: -130.6M Q3 '22: 74.5M Q4 '22: -34.8M Q1 '23: 130M Q2 '23: -23.3M Q3 '23: 69.7M Q4 '23: 126M Q1 '24: -13.6M Q2 '24: 29M Q3 '24: 124.8M Q4 '24: 102.9M Q1 '25: -5.8M Q2 '25: 61M Q3 '25: 106.2M Q4 '25: 108.5M Q1 '26: -34.9M Q2 '26: -51.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q1 '20: 148M Q2 '20: 147.4M Q3 '20: 147.6M Q1 '21: 151.2M Q2 '21: 152M Q3 '21: 149.3M Q1 '22: 149.9M Q2 '22: 151M Q3 '22: 151.4M Q1 '23: 152.1M Q2 '23: 154.9M Q3 '23: 159.7M Q1 '24: 307.3M Q2 '24: 319M Q3 '24: 309.6M Q1 '25: 324M Q2 '25: 322.4M Q3 '25: 324.8M Q1 '26: 328.9M Q2 '26: 328.1M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.05 -0.70 -0.35 0.00 0.35 0.70 1.05 Q3 '20: 0.41 Q4 '20: 0.61 Q1 '21: -0.13 Q2 '21: 0.05 Q3 '21: 0.08 Q4 '21: 0.07 Q1 '23: -0.90 Q2 '23: -0.02 Q3 '23: 0.06 Q4 '23: -0.48 Q1 '24: -0.73 Q2 '24: -0.79 Q3 '24: -0.85 Q4 '24: -0.38 Q1 '25: -0.04 Q2 '25: 0.01 Q3 '25: 0.02 Q4 '25: 0.23 Q1 '26: 0.38 Q2 '26: 0.49 Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.